Safety and Efficacy of Ferric Carboxymaltose in Anemic Pregnant Women: A Retrospective Case Control StudyReportar como inadecuado

Safety and Efficacy of Ferric Carboxymaltose in Anemic Pregnant Women: A Retrospective Case Control Study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Obstetrics and Gynecology InternationalVolume 2015 2015, Article ID 728952, 7 pages

Research ArticleDepartment of Obstetrics and Gynecology, Academisch Medisch Centrum, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands

Received 6 August 2015; Revised 8 November 2015; Accepted 10 November 2015

Academic Editor: Enrique Hernandez

Copyright © 2015 Anouk Pels and Wessel Ganzevoort. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Anemia during pregnancy is commonly caused by iron deficiency and can have severe consequences for both the mother and the developing fetus. The aim of this retrospective study was to assess the safety and efficacy of intravenous ferric carboxymaltose FCM in pregnant women. Methods. All women treated with FCM for anemia during pregnancy between 2010 and 2012 at our institution were included. A matched control group was selected, including women who either were nonanemic or had anemia but were not considered for intravenous iron. Main outcome measures were maternal safety and pregnancy outcomes. Results. The study included 128 patients FCM: 64; control: 64. Median FCM dose was 1000 mg and median gestational age at the time of first treatment was 34 weeks and 6 days. Median Hb increased from 8.4 g-dL interquartile range 7.7; 8.9 g-dL at the first FCM administration to 10.7 g-dL 9.8; 11.5 g-dL; with available Hb at delivery at the time of delivery, achieving levels similar to those in the control group 10.8 g-dL 9.8; 11.8 g-dL; . No treatment-related adverse events were reported and no statistically significant differences in pregnancy outcomes were observed between groups. Conclusions. Within the limitations of this case control study, FCM was a safe and efficient treatment of anemia during pregnancy.

Autor: Anouk Pels and Wessel Ganzevoort



Documentos relacionados